Amantadine and L-DOPA-induced Dyskinesia in Early Parkinson's Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

210

Participants

Timeline

Start Date

March 4, 2012

Primary Completion Date

February 20, 2018

Study Completion Date

February 26, 2019

Conditions
Parkinson Disease
Interventions
DRUG

Amantadine

200mg / day once daily in the morning and at noon - oral administration -

DRUG

placebo

200mg / day once daily in the morning and at noon - oral administration -

Trial Locations (18)

11108

CH de Narbonne, Narbonne

13385

Hopital de la Timone, Marseille

13616

CHG Aix en Provence, Aix-en-Provence

21079

CHU Dijon, Dijon

31000

CHU de Toulouse, Toulouse

33604

CHU de Bordeaux, Bordeaux

34295

hopital Saint Eloi, Montpellier

44093

CHu de Nantes, Nantes

46005

CH Jean Rougier, Cahors

59037

CHU Lille, Lille

63003

CHU Clermont-Ferrand, Clermont-Ferrand

69003

Hopital Lyon, Lyon

75013

Hopital pitié Salpétriére, Paris

76031

CH Charles Nicolle, Rouen

82013

CH Montauban, Montauban

86021

Hopital Jean Bernard, Poitiers

87042

CHU Dupuytren, Limoges

Unknown

CHU de Strasbourg, Strasbourg

All Listed Sponsors
lead

University Hospital, Toulouse

OTHER

NCT01538329 - Amantadine and L-DOPA-induced Dyskinesia in Early Parkinson's Disease | Biotech Hunter | Biotech Hunter